• Tenax Therapeutics posted a net loss of $15.7 million for first-quarter 2026, widening from $10.4 million a year earlier; loss per share was $0.35 versus $0.28.
• R&D expenses more than doubled to $11.5 million on higher clinical and preclinical development costs tied to Phase 3 LEVEL and global Phase 3 LEVEL-2, partly offset by lower stock-based compensation.
• G&A expenses fell to $5.0 million from $5.7 million, reflecting lower stock-based compensation timing, partly offset by higher salary and benefits.
• Cash and cash equivalents rose to $118.8 million at March 31, extending expected cash runway through at least first-quarter 2028.
• Phase 3 LEVEL study completed randomization of more than 230 patients, keeping Tenax on track to report topline data in third-quarter 2026; LEVEL-2 enrollment completion is anticipated by end of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120700PRIMZONEFULLFEED9717757) on May 12, 2026, and is solely responsible for the information contained therein.